Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment with sacubitril/valsartan reduces Insulin-Like Growth Factor Binding Protein-7 concentrations in management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study

Next Previous
Trial Profile

Treatment with sacubitril/valsartan reduces Insulin-Like Growth Factor Binding Protein-7 concentrations in management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan (Primary)
  • Indications Heart failure
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PARAMOUNT

Most Recent Events

  • 17 May 2021 Results assessing prevalence of high risk TTR-CA score from HFpEF clinical trials: I-PRESERVE, PARAMOUNT, PARAGON and TOPCAT presented at the 70th Annual Scientific Session of the American College of Cardiology
  • 28 Nov 2017 New trial record
  • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top